In vitro activity of the novel lactone ketolide nafithromycin (WCK 4873) against contemporary clinical bacteria from a global surveillance program

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 12, 2017, Pages

  Flamm, R K ^a   Rhomberg, P R ^a   Sader, H S ^a  

^a JMI LABORATORIES   (United States)

Author keywords

Ketolides; Streptococcus pneumoniae; Streptococcus pyogenes

Indexed keywords

AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LINEZOLID; NAFITHROMYCIN; OXACILLIN; TELITHROMYCIN; VANCOMYCIN; WCK 4873; ANTIINFECTIVE AGENT; KETOLIDE; LACTONE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; DRUG POTENCY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; BACTERIAL PNEUMONIA; COMMUNITY ACQUIRED INFECTION; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; LACTONES; MICROBIAL SENSITIVITY TESTS; MORAXELLA (BRANHAMELLA) CATARRHALIS; PNEUMONIA, BACTERIAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UNITED STATES;

EID: 85035020881     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01230-17     Document Type: Article

References (21)

1. Farrell DJ, Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2016. In vitro activity of lactone ketolide WCK 4873 when tested against contemporary community-acquired bacterial pneumonia pathogens from a global surveillance program, abstr Sunday-476. ASM Microbe, Boston, MA.
2. Farrell DJ, Sader HS, Rhomberg PR, Flamm RK, Jones RN. 2016. In vitro activity of WCK 4873 (nafithromycin) against resistant subsets of Streptococcus pneumoniae from a global surveillance program (2014), abstr Saturday-455. ASM Microbe, Boston, MA.
3. Chugh R, Gupta M, Iwanowski P, Bhatia A. 2016. Nafithromycin phase 1 multiple ascending dose study in healthy subjects, abstr Monday-513. ASM Microbe, Boston, MA.
4. Bhatia A, Chugh R, Gupta M, Iwanowski P. 2016. Nafithromycin single ascending dose (SAD) and food effect (FE) study in healthy subjects, abstr Monday-514. ASM Microbe, Boston, MA.
5. Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ. 2002. The ketolides: a critical review. Drugs 62:1771–1804. https://doi.org/10.2165/00003495-200262120 -00006.
6. Krokidis MG, Marquez V, Wilson DN, Kalpaxis DL, Dinos GP. 2014. Insights into the mode of action of novel fluoroketolides, potent inhibitors of bacterial protein synthesis. Antimicrob Agents Chemother 58:472– 480. https://doi.org/10.1128/AAC.01994-13.
7. Rodgers W, Frazier AD, Champney WS. 2013. Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob Agents Chemother 57:1632–1637. https://doi.org/10.1128/AAC.02316-12.
8. Douthwaite S. 2001. Structure-activity relationships of ketolides vs. macrolides. Clin Microbiol Infect 7(Suppl 3):S11–S17.
9. Fernandes P, Martens E, Bertrand D, Pereira D. 2016. The solithromycin journey—it is all in the chemistry. Bioorg Med Chem Lett 24: P6420–P6428. https://doi.org/10.1016/j.bmc.2016.08.035.
10. Sader HS, Farrell DJ, Flamm RK, Jones RN. 2016. Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US medical centers. Surg Infect (Larchmt) 17:443–447. https://doi.org/10.1089/sur.2015.209.
11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM, Jr, Musher DM, Niederman MS, Torres A, Whitney CG. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72. https://doi.org/10.1086/511159.
12. Jones RN, Sader HS, Mendes RE, Flamm RK. 2013. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998 –2011). Diagn Microbiol Infect Dis 75: 107–109. https://doi.org/10.1016/j.diagmicrobio.2012.08.024.
13. Farrell DJ, Mendes RE, Rhomberg PR, Jones RN. 2014. Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies. Antimicrob Agents Chemother 58:5547–5551. https://doi.org/10.1128/AAC.03172-14.
14. CDC. 2013. Antibiotic resistance threats in the United States. CDC, Atlanta, GA.
15. File TM, Jr. 2006. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 12(Suppl 3):S31–S41.
16. Brinker AD, Wassel RT, Lyndly J, Serrano J, Avigan M, Lee WM, Seeff LB. 2009. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases. Hepatology 49:250–257. https://doi.org/10.1002/hep.22620.
17. Khande H, Satav J, Kulkarni A, Bhagwat S, Patel M. 2017. WCK 4873 (nafithromycin): impact of hyper ermB induction in S. pneumoniae and S. aureus on the activity of ketolides, abstr P1350. ECCMID, Vienna, Austria.
18. Chugh R, Bhatia A, Gupta M, Sharma N, Gotfried M, Rodvold K. 2016. Nafithromycin (WCK 4873) concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy subjects, abstr Monday-506. ASM Microbe, Boston, MA.
19. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—10th ed. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.
20. CLSI. 2016. M100-S26. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
21. EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, January 2016. European Committee on Antimicrobial Susceptibility Testing. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.xls.